Altimmune, Inc., a clinical-stage biopharmaceutical company, has entered into an agreement with Lonza for the manufacturing of AdCOVID, Altimmune’s next-generation single-dose intranasal vaccine candidate for COVID-19.   AdCOVID is a single-dose COVID-19 vaccine candidate that has the potential to be conveniently administered via an intranasal spray. In addition to activating systemic immunity (neutralizing antibodies and T cell responses), AdCOVID stimulates a type of localized immunity calle...